Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival outcomes in isolated severe tricuspid regurgitation according to therapeutic modalities: a systematic review and meta-analysis.

Open heart·2025
Same author

Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.

Journal of the American College of Cardiology·2024
Same author

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

The New England journal of medicine·2024
Same author

Sex-related differences in severe native valvular heart disease: the ESC-EORP Valvular Heart Disease II survey.

European heart journal·2024
Same author

Management of Massive Thrombosis of a Tendyne Valve: The Importance of Heart Valve Centers.

JACC. Case reports·2024
Same author

Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.

European journal of heart failure·2024
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.7K

Mitral valve disease--current management and future challenges.

Rick A Nishimura1, Alec Vahanian2, Mackram F Eleid1

  • 1Mayo Clinic, Rochester, MN, USA.

Lancet (London, England)
|March 31, 2016
PubMed
Summary
This summary is machine-generated.

Mitral valve disease management is evolving with advanced imaging and treatments like surgical repair and transcatheter mitral valve repair (MitraClip). Future directions focus on optimizing care for primary and secondary mitral regurgitation, including transcatheter techniques.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.5K

Related Experiment Videos

Last Updated: May 12, 2026

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.7K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.5K

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Interventional Cardiology

Background:

  • Mitral valve disease diagnosis and management are rapidly advancing.
  • Improved imaging and understanding of pathology enable earlier diagnosis and complex treatments.
  • Primary mitral regurgitation management focuses on surgical repair, while secondary mitral regurgitation presents a less clear future.

Purpose of the Study:

  • To review the current state and future directions in the diagnosis and management of mitral valve disease.
  • To highlight advancements in surgical and transcatheter interventions for mitral regurgitation.
  • To discuss the challenges and emerging treatments for mitral annular calcification.

Main Methods:

  • Review of current literature and clinical trial findings.
  • Analysis of established and emerging treatment modalities for mitral regurgitation.
  • Discussion of the role of imaging in mitral valve disease assessment.

Main Results:

  • Surgical repair remains the standard for primary mitral regurgitation, with high success rates expected.
  • Transcatheter mitral valve repair (MitraClip) shows promise for high-risk patients and is being studied in intermediate-risk groups.
  • Transcatheter techniques for both repair and replacement are expected to expand, especially for mitral annular calcification.

Conclusions:

  • The next five years will likely see optimized surgical repair for primary mitral regurgitation and expanded use of transcatheter interventions.
  • Further clinical trials are crucial to clarify management strategies for secondary mitral regurgitation.
  • Transcatheter approaches offer new possibilities for treating complex mitral valve disease, including mitral annular calcification.